Elanco Animal Health Inc (N:ELAN)

Apr 17, 2024 08:00 am ET
Elanco Confirms Date and Conference Call for First Quarter 2024 Financial Results Announcement
GREENFIELD, Ind., April 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.
Apr 01, 2024 06:30 am ET
Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors
New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee
Mar 05, 2024 10:15 am ET
The Cow is the How: Elanco Sees Methane Reduction as New Value Opportunity
NORTHAMPTON, MA / ACCESSWIRE / March 5, 2024 / Elanco Animal Health CEO, Jeff Simmons joins Jim Cramer on Mad Money to discuss the company's commitment to create solutions for farmers and ranchers that can reduce, measure, and monetize greenhouse gas emissions, including methane, which can help create new value to farmers and the food chain, as well as climate-neutral farms.
Feb 29, 2024 08:00 am ET
Ancora Nominates Four Highly Qualified, Independent Director Candidates and Urges Orderly CEO Succession at Elanco Animal Health
Ancora Holdings Group, LLC (together with its affiliates, “Ancora” or “we”), which owns approximately 3% of the outstanding common stock of Elanco Animal Health Incorporated (NYSE: ELAN) (“Elanco” or the “Company”), today issued the below statement regarding its nomination of four highly qualified, independent candidates for election to the Company’s Board of Directors (the “Board”) at the 2024 Annual Meeting of Shareholders (the “Annual Meeting”). Ancora has also released a presentation, entitled “Overview: The Case for Change at Elanco’s 2024 Annual Meeting
Feb 26, 2024 05:27 am ET
Elanco Animal Health Reports Fourth Quarter and Full Year 2023 Results
Fourth Quarter 2023 Financial Results:Revenue of $1,035 millionReported Net Loss of $141 million, Adjusted Net Income of $39 millionAdjusted EBITDA of $165 million or 15.9% of RevenueReported EPS of $(0.29), Adjusted EPS of $0.08 Net leverage ratio of 5.6x Adjusted EBITDAFull Year 2023 Financial Results:Revenue of $4,417 millionReported Net Loss of $1,231 million, Adjusted Net Income of $439 millionAdjusted EBITDA of $979 million or 22.2% of RevenueReported EPS of $(2.50), Adjusted EPS of $0.89 Full Year 2024 Guidance:Revenue of $4,450 to $4,540 millionReported Net Loss of $17 to $62 million
Feb 22, 2024 07:00 am ET
Elanco to Participate in Upcoming Investor Conferences
GREENFIELD, Ind., Feb. 22, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences.
Feb 09, 2024 10:15 am ET
Athian and Elanco Animal Health Team Up to Transform Food Production through Methane Reduction
CEOs speaking at Reuters Transform Food Today Announce the First-of-its-Kind Livestock Carbon Inset Market has First Carbon Credits Verified for Sale
Feb 08, 2024 01:46 pm ET
Beef 'agtech' company Cattler launches interface with Elanco for its Benchmark program
SARATOGA, Calif., Feb. 8, 2024 /PRNewswire/ -- Cattler (www.cattler.farm) announces the launch of its interface with Elanco Animal Health Incorporated (NYSE: ELAN), as part of the agreement reached September 2023, to provide data collaboration for customers participating in Elanco Knowledge Solutions (EKS) services that include (but are not limited to) Benchmark TM and Experior TM Data Services. This interface provides Cattler customers with a streamlined access to comparability in these trusted Elanco services and is designed to deliver continuous data to help cattle feeders optimize their
Feb 08, 2024 07:00 am ET
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2023 Financial Results Announcement
GREENFIELD, Ind., Feb. 8, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2023 financial results on Monday, February 26, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.
Feb 07, 2024 01:25 pm ET
Elanco CEO, Jeff Simmons Launches Mission to Save 1 Million Puppies from Deadly Parvo
NORTHAMPTON, MA / ACCESSWIRE / February 7, 2024 / Elanco:
Feb 05, 2024 06:33 am ET
Merck Animal Health to Acquire Elanco’s Aqua Business
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN) for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. The acquisition is expected to be completed by mid-year 2024, su
Feb 05, 2024 05:33 am ET
Elanco Announces Sale of Aqua Business for $1.3 Billion
Transaction reinforces Elanco's commitment to most significant value creation opportunities in pet health and livestock sustainability
Jan 17, 2024 07:30 am ET
Elanco Launches Multi-Year Mission to Save 1 Million Puppies from Canine Parvovirus
Calling all Veterinarians and Pet Lovers - Take the "Defend Puppies. Defeat Parvo." Pledge Today to Save Puppies from Deadly Canine Parvovirus 
Jan 02, 2024 07:33 am ET
Dec 19, 2023 08:00 am ET
Elanco to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 8-10, 2024. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts on Tuesday, January 9, 2024 at 3:00 p.m. PST (6:00 PM EST).
Nov 27, 2023 08:00 am ET
Elanco to Participate in Evercore ISI 6th Annual HealthCONx Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Evercore ISI 6th Annual HealthCONx Conference, November 28-29, 2023. Todd Young, Executive Vice President and CFO, will participate in a fireside chat on Wednesday, November 29 at 8:20 a.m. ET.
Nov 07, 2023 06:33 am ET
Elanco Animal Health Reports Third Quarter 2023 Results
Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2023, provided guidance for the fourth quarter of 2023, and updated guidance for the full year 2023.
Nov 02, 2023 08:00 am ET
Bexacat™ (bexagliflozin tablets), the First and Only Tablet to Treat Feline Diabetes, Named “Overall Cat Health Product Of The Year” In 2023 Pet Innovation Awards
The Pet Innovation Awards, an independent recognition platform highlighting the most innovative companies, services, and products in the highly competitive Pet Care industry, today announced it has awarded “Overall Cat Health Product of the Year”...
Nov 02, 2023 07:16 am ET
Athian and Elanco Animal Health Team Up to Transform Food Production through Methane Reduction
Athian (athian.ai) announced today the establishment of the first-of-its-kind voluntary livestock carbon insetting marketplace, with the first accepted protocol aimed at reducing enteric methane emissions and improving feed utilization by using innovative feed management products from Elanco Animal Health (NYSE: ELAN). This new carbon marketplace creates an opportunity for farmers to monetize their greenhouse gas emission reductions.
Oct 17, 2023 08:00 am ET
Elanco Confirms Date and Conference Call for Third Quarter 2023 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2023 financial results on Tuesday, November 7, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Oct 04, 2023 06:30 am ET
Elanco Announces Corporate Governance Enhancements
Elanco Animal Health Incorporated (NYSE: ELAN) announced today that the Board of Directors has commenced a process to amend the Company’s corporate governing documents as part of a comprehensive governance review following the Company’s 2023 Annual Meeting of Shareholders. The Board expects to seek shareholder approval at the 2024 Annual Meeting of Shareholders for amendments to the Company’s Articles of Incorporation that will:
Sep 07, 2023 04:15 pm ET
Elanco Launches Varenzin™-CA1 (molidustat oral suspension) – the First-of-its-Kind Oral Treatment for Anemia in Cats with Chronic Kidney Disease
Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced that the first shipments of Varenzin™-CA1 (molidustat oral suspension), conditionally approved by U.S. Food and Drug Administration (FDA) as the first and only treatment to control non-regenerative anemia in cats with chronic kidney disease (CKD), are shipping to veterinary clinics around the country. Anemia from CKD can dramatically affect a cat’s existence, making them lethargic, reducing their appetite, and even leading to a rapid heart rate and difficulty breathing in severe cases. According to the FDA, CKD-related anemia is a
Sep 05, 2023 05:00 pm ET
Elanco to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023 and Tuesday, September 12, 2023. Jeff Simmons, president and CEO, will participate in a fireside chat on Monday at 4:15 p.m. ET.
Aug 07, 2023 06:33 am ET
Elanco Animal Health Reports Second Quarter 2023 Results and Raises Full Year Guidance
Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2023, provided guidance for the third quarter of 2023, and raised guidance for the full year 2023.
Jul 20, 2023 08:00 am ET
Elanco Releases 2022 Environmental, Social and Governance Report, Demonstrating Sustainability Progress in Internal Operations and Customer Collaborations
Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2022 Environmental, Social and Governance (ESG) Report highlighting enhanced governance, transparency
Jul 18, 2023 08:00 am ET
Elanco Confirms Date and Conference Call for Second Quarter 2023 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2023 financial results on Monday, August 7, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Jul 14, 2023 09:31 am ET
Thinking about trading options or stock in Palantir Technologies, SoundHound AI, Tesla, Elanco Animal Health, or JD.Com?
NEW YORK, July 14, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLTR, SOUN, TSLA, ELAN, and JD.
Jul 13, 2023 05:24 pm ET
Environmental Protection Agency (EPA) Completes Review of Seresto® Collar and Confirms Continued Registration; Data Affirms Safety Profile of the Product
Elanco Animal Health Incorporated (NYSE: ELAN) and the U. S. Environmental Protection Agency (EPA) today announced that EPA, with support from the Food and Drug Administration (FDA), has completed its comprehensive, multi-year review of the Seresto® flea and tick collar. EPA confirms continued registration of the collar. Comprehensive data affirms the safety profile of Seresto.
Jun 05, 2023 08:00 am ET
Elanco to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023. Jeff Simmons, President and CEO, will participate in a fireside chat on Monday, June 12 at 5:40 p.m. ET (2:40 p.m. PT).
May 25, 2023 08:00 am ET
Elanco to Participate in Stifel 2023 Jaws and Paws Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Stifel 2023 Jaws and Paws Conference on Thursday, June 1, 2023. Todd Young, executive vice president and CFO, will participate in a fireside chat at 1:50 p.m. ET.
May 09, 2023 06:34 am ET
Elanco Animal Health Reports First Quarter 2023 Results
Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2023, provided guidance for the second quarter of 2023, and raised the bottom-end of guidance for the full year 2023.
May 02, 2023 08:30 am ET
Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus
Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) has provided a conditional license for the first Canine Parvovirus Monoclonal Antibody. This is the first and only approved therapeutic solution proven to treat canine parvovirus — one of the most contagious and deadly viruses a dog can contract with a 91% mortality rate if not treated with supportive carei. The treatment is the first monoclonal antibody for Elanco, an important innovation platform for the company.
May 01, 2023 07:34 pm ET
California Dairies, Inc. and DSM Venturing Complete Strategic Investment in Athian
Athian's livestock carbon credit marketplace completes latest round of funding thanks to the investment by California Dairies, Inc. and DSM Venturing
Apr 18, 2023 08:00 am ET
Elanco Confirms Date and Conference Call for First Quarter 2023 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2023 financial results on Tuesday, May 9, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Mar 14, 2023 08:00 am ET
Tyson Ventures invests in Athian's cloud-based carbon credit marketplace for livestock sector
Will help fund ground-breaking solution to reward livestock producers for certified greenhouse gas reductions
Mar 09, 2023 08:00 am ET
Elanco to Participate in the Barclays Global Healthcare Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Barclays Global Healthcare Conference on March 14-15, 2023. Todd Young, executive vice president and CFO, will participate in a fireside chat on Tuesday, March 14 at 8:30 a.m. ET.
Feb 27, 2023 08:00 am ET
Elanco to Participate in the Cowen 43rd Annual Health Care Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Cowen 43rd Annual Health Care Conference on March 6-7, 2023. Jeff Simmons, president and CEO, will participate in a fireside chat on Monday, March 6 at 2:10 p.m. ET.
Feb 23, 2023 04:45 pm ET
Elanco to Participate in the Bank of America 2023 Animal Health Summit
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Bank of America 2023 Animal Health Summit on Thursday, March 2, 2023. Jeff Simmons, president and CEO, and Todd Young, executive vice president and CFO, will represent the company and respond to questions from analysts at 4:40 p.m. ET.
Feb 21, 2023 06:30 am ET
Elanco Animal Health Reports Fourth Quarter and Full Year 2022 Results
Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2022, and provided initial guidance both for the first half and full year 2023.
Feb 20, 2023 04:30 pm ET
Elanco Adds Animal Health Veteran to Executive Committee
Elanco Animal Health (NYSE: ELAN) announced today the appointment of Tim Bettington as the company’s executive vice president Corporate Strategy and Market Development. He will join Elanco’s executive committee on March 20.
Feb 03, 2023 08:30 am ET
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2022 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Jan 03, 2023 08:00 am ET
Elanco to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts at 12:45 p.m. ET.
Dec 09, 2022 10:48 am ET
Elanco Announces FDA Approval of Bexacat™ (bexagliflozin tablets) – the First-of-its-Kind Oral Feline Diabetes Treatment Option
Today Elanco Animal Health (NYSE:ELAN) announced the U.S. Food and Drug Administration (FDA) approved Bexacat™ (bexagliflozin tablets), the first orally administered prescription medication to improve glycemic control in cats with diabetes mellitus, expanding Elanco’s innovative feline portfolio while addressing an unmet need for this chronic condition in adult cats.
Nov 16, 2022 08:00 am ET
Elanco to Participate in Evercore ISI 5th Annual HealthCONx Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022. Jeff Simmons, president and CEO, will participate in a fireside chat at 8:50 a.m., Eastern time.
Nov 08, 2022 06:30 am ET
Elanco Animal Health Reports Third Quarter 2022 Results
Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2022, provided guidance for the fourth quarter of 2022, and updated guidance for the full year 2022.
Oct 11, 2022 08:00 am ET
Elanco Confirms Date and Conference Call for Third Quarter 2022 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2022 financial results on Tuesday, November 8, 2022. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Sep 08, 2022 08:00 am ET
Elanco Announces Changes to its Board of Directors
Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Scott Ferguson, founder and managing partner of Sachem Head Capital Management LP (“Sachem Head”), is stepping down from the Board of Directors in connection with Ferguson and Sachem Head refocusing his time across other Sachem Head Board commitments. As one of the Company’s largest shareholders, Sachem Head will continue to engage with and be a resource for the Board and management team.
Sep 01, 2022 08:00 am ET
Elanco to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022. Jeff Simmons, president and CEO, will participate in a fireside chat at 2:50 p.m., Eastern time.
Aug 16, 2022 08:00 am ET
Elanco Releases 2021 Environmental, Social and Governance Report Highlighting Progress on Healthy Purpose™ Goals
Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2021 Environmental, Social and Governance (ESG) Report “Changing The World One Animal at a Time” highlighting the company’s progress on relevant ESG t
Aug 08, 2022 06:30 am ET
Elanco Animal Health Reports Second Quarter 2022 Results
Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2022, provided guidance for the third quarter of 2022, and updated guidance for the full year 2022.
Jul 18, 2022 06:30 am ET
Elanco Confirms Date and Conference Call for Second Quarter 2022 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2022 financial results on Monday, August 8, 2022. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Jul 12, 2022 11:25 am ET
Elanco Survey Finds Many Pets Live Unprotected Against Preventable Diseases
Amidst a surge of pet adoptions, a new survey released by Elanco finds many pets are insufficiently protected against common diseases like Lyme and leptospirosis. Once largely isolated to wooded regions, the threat of Lyme and lepto has escalated in urban and suburban areas due to expanding tick populations across the country.
Jun 07, 2022 07:30 am ET
New Anthem from Seresto Could be the 2022 Song of the Summer
Each long-awaited summer brings a new, upbeat anthem for blaring with the car windows down or tapping your paws on the trail. This summer’s anthem is for the dogs and cats. Released today by some of the most popular pets on Instagram including @KellyBove,
Jun 06, 2022 06:30 am ET
Elanco to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Goldman Sachs 43rd Annual Global Healthcare Conference, June 13-14, 2022. Todd Young, executive vice president and CFO, will participate in a fireside chat on Monday, June 13 at 6:20 p.m. ET (3:20 p.m. PT).
May 23, 2022 06:30 am ET
Elanco to Participate in Stifel 2022 Jaws and Paws Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Stifel 2022 Jaws and Paws Conference on Wednesday, June 1, 2022. Jeff Simmons, president and CEO, will participate in a fireside chat at 3:00 p.m. ET.
May 09, 2022 06:30 am ET
Elanco Animal Health Reports First Quarter 2022 Results
Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2022, provided guidance for the second quarter of 2022, and updated guidance for the full year 2022.
Apr 27, 2022 01:00 am ET
Elanco and Royal DSM Announce Strategic Alliance in U.S. for Bovaer® – A Revolutionary, Methane-Reducing Feed Product for Cattle
Elanco Animal Health Incorporated (ELAN: NYSE) and Royal DSM have created a strategic alliance connecting two leading, sustainability-focused companies to address one of society’s most significant opportunities of the decade, mitigating climate change by reducing greenhouse gas emissions from farming. Elanco has secured the exclusive U.S. licensing rights to develop, manufacture and commercialize Bovaer® for beef and dairy cattle.
Apr 14, 2022 06:30 am ET
Elanco Confirms Date and Conference Call for First Quarter 2022 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2022 financial results on Monday, May 9, 2022. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Apr 12, 2022 10:30 am ET
Elanco Breaks Ground on State-of-the-Art Campus, Creating Indianapolis’ Newest Landmark
Elanco Animal Health Incorporated (NYSE: ELAN) today unveiled plans for its new global headquarters featuring environmentally-sustainable, employee-focused design and a state-of-the art innovation center.
Apr 12, 2022 06:30 am ET
Elanco Animal Health Incorporated Announces Early Results of Tender Offer and Increase in Tender Cap for 2023 Notes
Elanco Animal Health Incorporated (NYSE: ELAN) (“Elanco”) today announced that as of 5:00 p.m., New York City time, on April 11, 2022 (the “Early Tender Time”), holders of approximately $406,391,000 aggregate principal amount, or approximately 54.19% of the outstanding principal amount, of its outstanding 4.272% Senior Notes due 2023 (the “Notes”) had tendered their Notes pursuant to Elanco’s previously announced tender offer (the “Offer”).
Apr 11, 2022 07:00 am ET
Elanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology
BiomEdit intends to discover and develop animal health products that leverage microbiome science to improve animal health, animal protein production, and livestock disease monitoring
Mar 29, 2022 05:57 pm ET
Elanco Animal Health Incorporated Announces Tender Offer for 2023 Notes
Elanco Animal Health Incorporated (NYSE: ELAN) (“Elanco”) today announced the commencement of a cash tender offer (the “Offer”) for up to $250 million aggregate principal amount of its 4.272% Senior Notes due 2023 (CUSIP No. 28414HAE3) (the “Notes”), upon the terms and conditions set forth in the Offer to Purchase dated March 29, 2022.
Mar 16, 2022 08:30 am ET
Elanco Expands Commitment to Creating Shared Value, Launches New Initiative Empowering Small-Scale Producers in Sub-Saharan Africa
Elanco Animal Health Incorporated (ELAN: NYSE) today announces the expansion of its shared value footprint across Sub-Saharan Africa, delivering on its 2030 pledge to create sustainable development solutions for those who depend on livestock for their livelihoods.
Feb 24, 2022 06:30 am ET
Elanco Animal Health Reports Fourth Quarter and Full Year 2021 Results
Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2021, and provided initial guidance both for the first quarter and full year 2022.
Feb 22, 2022 04:35 pm ET
Elanco Announces the Addition of Rajeev (Bobby) Modi to Lead U.S. Pet Health
Elanco Animal Health (NYSE: ELAN) announced today the appointment of Rajeev (Bobby) Modi as the company’s executive vice president U.S. Pet Health and Global Digital Transformation. He will join the company on March 14 and will serve on the company’s executive committee.
Feb 21, 2022 06:30 am ET
Elanco to Participate in the Cowen 42nd Annual Health Care Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 2:50 p.m. ET.
Feb 18, 2022 05:30 am ET
Scout Bio Appoints Life Sciences Executive Aaron Schacht to Board of Directors
Scout Bio, a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions announced it had appointed Aaron Schacht to its Board of Directors. Mr. Schacht is a deeply experienced life...
Feb 08, 2022 11:10 am ET
TriRx Completes Acquisition of Elanco Manufacturing Facility in Speke, United Kingdom
NORWALK, Conn., Feb. 8, 2022 /PRNewswire/ -- TriRx Pharmaceutical Services, LLC, a leading international CDMO, announced today that it has finalized and closed on its agreement with Elanco Animal Health Incorporated (NYSE:ELAN) to acquire the ownership and operations of its manufacturing site in Speke, United Kingdom. Elanco is one of the world's leading animal health companies, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The two companies agreed a two-facilty sale and long-term supply agreement in 2021, covering a fa
Feb 07, 2022 08:30 am ET
Elanco Adds New Tools to Advance U.S. Livestock Sustainability Efforts
As the urgent, time-sensitive issues of hunger and climate change lead headlines around the world, Elanco Animal Health (NYSE: ELAN) announces two new resources aimed at helping the cattle industry make a positive impact.
Feb 04, 2022 06:30 am ET
Elanco to Participate in the BofA Securities 2022 Virtual Animal Health Summit
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the BofA Securities 2022 Virtual Animal Health Summit on Thursday, February 24, 2022. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 1:35 p.m. ET.
Feb 03, 2022 06:30 am ET
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2021 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Jan 20, 2022 04:30 pm ET
Elanco’s ZORBIUM™ (Buprenorphine Transdermal Solution) – the First Long-Acting Transdermal Buprenorphine for Cats - Gains U.S. Approval
With the U.S. Food and Drug Administration (FDA) approval of Zorbium™ (buprenorphine transdermal solution), Elanco Animal Health (NYSE: ELAN) expands its pain management offerings while addressing an unmet need for veterinary practices.
Jan 04, 2022 04:30 pm ET
Elanco to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. ET.
Nov 30, 2021 07:00 am ET
Elanco Announces Changes to Simplify Organizational Structure, Drive Profitable Growth and Focus Investments on Growth and Innovation Opportunities
Elanco Animal Health Incorporated (NYSE: ELAN) today announced proposed structural changes to simplify the organization as it best positions the company to create long-term value.
Nov 16, 2021 08:30 am ET
Elanco to Participate in the Evercore ISI 4th Annual HealthCONx Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 1:50 p.m. ET.
Nov 08, 2021 09:00 am ET
Elanco Joins Newly-Formed Consortium Advancing Climate-Neutral Cattle Innovation
Led by the Foundation for Food & Agriculture Research (FFAR), each member of the consortium will review applications, commit funding to research ideas that show promise, and hold the option to further fund and develop individual projects, a collaborative effort that will speed innovation in an area where every second matters. According to the United Nations1, the world must begin significantly reducing emissions in this decade to prevent irreversible damage to the planet.
Nov 05, 2021 06:30 am ET
Elanco Animal Health Reports Third Quarter 2021 Results Exceeding Revenue Guidance; Raising Full Year 2021 Revenue Guidance
Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2021, provided guidance for the fourth quarter of 2021, and updated guidance for the full year 2021. The results reflect the inclusion of the Bayer Animal Health business Elanco acquired on August 1, 2020.
Oct 18, 2021 04:15 pm ET
Elanco Animal Health Selected for 2021 FORTUNE’s Change the World List
Elanco Animal Health Incorporated (NYSE: ELAN) today announces its inclusion in FORTUNE’s 2021 Change the World list, which recognizes companies that have made an important social or environmental impact through their profit-making strategy and operations.
Oct 07, 2021 08:30 am ET
Elanco Confirms Date and Conference Call for Third Quarter 2021 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2021 financial results on Friday, November 5, 2021. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Oct 05, 2021 06:30 am ET
Elanco Announces New Innovation Leader, Additional Strategic Move to Increase Focus on High-Value, Late-Stage Pet Health Pipeline Progress
Elanco Animal Health Incorporated (NYSE: ELAN) today announced Ellen de Brabander, Ph.D., will become the new executive vice president of Innovation and Regulatory Affairs. de Brabander brings a proven background of accomplishment in animal health research and development, including the development of parasiticide blockbuster NexGard, as well as major vaccine products in Pet Health and Farm Animal. Current executive vice president Aaron Schacht will lead the initiative to carve out Elanco’s microbiome R&D platform as an independent biopharmaceutical company focused on developing solutions for
Sep 29, 2021 08:30 am ET
Climate-Neutral Beef, Dairy Could Reach Store Shelves by 2050, According to New Research
A newly-published white paper, “Pathway to Climate Neutrality for U.S. Beef and Dairy Cattle Production” by Drs. Sara E. Place, chief sustainability officer
Sep 22, 2021 04:15 pm ET
Animal Agriculture Accepts Challenge to Be Climate Change Solution while Delivering Global Nutrition Needs
Today, more than 20 global leaders from one of the world’s largest industries, animal agriculture, announced their intention to address the interconnected and urgent challenges of climate change and hunger. Signatories represent global meat, milk, fish and egg production — demonstrating their potential impact in addressing climate change and hunger.
Sep 16, 2021 01:00 pm ET
Business Leaders, Global Experts Convene in Effort to Move Livestock Production to Climate-Neutrality and Achieve Zero Hunger
Global leaders from one of the world’s largest industries converged this week at the Sustainable Solutions for Zero Hunger by 2030: A Vision for Animal Agriculture Forum to explore solutions to combat climate change while keeping the world nourished. Held ahead of the United Nation’s Food Systems Summit, more than 600 global business leaders, policymakers and key opinion leaders from a dozen countries convened to accelerate existing efforts moving livestock production toward climate-neutrality.
Aug 30, 2021 06:45 am ET
Elanco Closes Acquisition of Kindred Biosciences
Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Kindred Biosciences. The transaction advances Elanco’s access to the fast-growing $1+ billion dermatology market, complementing the company’s existing pipeline and increasing R&D capability in biologics and monoclonal antibodies.
Aug 25, 2021 08:30 am ET
Elanco to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 3:30 p.m. ET.
Aug 18, 2021 03:57 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Elanco Animal Health (ELAN) Investors to Contact Firm’s Attorneys Now, Firm Investigating Possible Securities Law Violations
Hagens Berman urges Elanco Animal Health, Inc. (NYSE: ELAN) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit:...
Aug 11, 2021 05:34 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elanco Animal Health Incorporated - ELAN
Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Aug 11, 2021 02:00 am ET
TriRx Hosted State and Community Leaders to Celebrate Acquisition of Shawnee, Kansas Facility
NORWALK, Conn., Aug. 11, 2021 /PRNewswire/ -- TriRx Pharmaceutical Services, LLC, a leading international CDMO, hosted Kansas Lt. Governor David Toland, Shawnee Mayor Michelle Distler, State Senator Mike Thompson, Congresswoman Jo Ella Hoye, Congresswoman Cindy Neighbor, other Shawnee city leaders, representatives from The University of Kansas, Kansas State University, and key customers at a ribbon-cutting ceremony, Tuesday, August 10.
Aug 10, 2021 08:00 pm ET
ELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating Elanco Animal Health Incorporated on Behalf of Elanco Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) on behalf of Elanco stockholders. Our investigation concerns whether Elanco has violated the federal securities laws and/or engaged in other unlawful business practices.
Aug 10, 2021 09:36 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Elanco Animal Health (ELAN) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations
SAN FRANCISCO, Aug. 10, 2021 /PRNewswire/ -- Hagens Berman urges Elanco Animal Health, Inc. (NYSE: ELAN) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. 
Aug 10, 2021 08:15 am ET
(ELAN) Elanco Animal Health Alert: Did You Lose Money on Your Investment? Contact Johnson Fistel Regarding Investigation
SAN DIEGO, Aug. 10, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN).
Aug 09, 2021 08:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elanco Animal Health Incorporated - ELAN
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Aug 09, 2021 03:27 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Elanco Animal Health Incorporated and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE:
Aug 09, 2021 03:24 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Elanco Animal Health (ELAN) Investors to Contact Firm’s Attorneys Now, Firm Investigating Possible Securities Law Violations
Hagens Berman urges Elanco Animal Health, Inc. (NYSE: ELAN) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.   Visit:...
Aug 09, 2021 06:30 am ET
Elanco Animal Health Reports Second Quarter 2021 Results
Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2021, provided guidance for the third quarter of 2021, and raised revenue guidance for the full year 2021. The results reflect the inclusion of the Bayer Animal Health business Elanco acquired on August 1, 2020.
Aug 02, 2021 02:00 am ET
TriRx Completes Acquisition of Elanco Animal Health Facility in Shawnee, Kansas
NORWALK, Conn., Aug. 2, 2021 /PRNewswire/ -- TriRx Pharmaceutical Services, LLC, a leading international CDMO, announced today that it has finalized and closed on an agreement with Elanco Animal Health Incorporated (NYSE:ELAN) to acquire the ownership and operations of its manufacturing site in Shawnee, Kansas. Elanco is a global animal health leader dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The two companies also entered into a long-term supply agreement for this site.
Jul 12, 2021 08:30 am ET
Elanco Confirms Date and Conference Call for Second Quarter 2021 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2021 financial results on Monday, August 9, 2021. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Jun 30, 2021 04:30 pm ET
Elanco Foundation Announces Partnership with the JBS Fund
Today, the Elanco Foundation announces a partnership with the JBS Fund for the Amazon (The Fund) to jointly support the RestaurAmazônia Project, which promotes sustainable farming and environmental conservation in the Amazon. Over the next three years, the Elanco Foundation will provide $450,000 to Solidaridad Network, the international civil society organization managing the project. Funds will support an initiative that combines cocoa cultivation with cattle raising in the State of Pará in Brazil to increase the income of rural farm families, preserve forest areas and reduce gr
Jun 23, 2021 12:01 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds KIN, FMBI, SLCT, and CNST Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th...
Jun 16, 2021 06:45 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kindred Biosciences, Inc.
NEW YORK, June 16, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kindred Biosciences, Inc. (NASDAQ: KIN) and its board of directors concerning the proposed acquisition of the company by Elanco Animal Health Incorporated (NYSE: ELAN). Stockholders will receive $9.25 for each share of Kindred Biosciences stock that they hold. The transaction is valued at approximately $440 million and is expected to close in the third quarter of 2021.
Jun 16, 2021 01:58 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Kindred Biosciences, Inc. Buyout
Rigrodsky Law, P.A. announces that it is investigating Kindred Biosciences, Inc. (“Kindred”) (NASDAQ CM: KIN) regarding possible breaches of fiduciary duties and other violations of law related to Kindred’s agreement to be acquired by Elanco Animal...
Jun 16, 2021 12:14 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Kindred Biosciences, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Kindred Biosciences, Inc. (“Kindred” or the “Company”) (NASDAQ: KIN) in connection with the proposed acquisition of the...
Jun 16, 2021 11:41 am ET
KINDRED BIOSCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of KIN and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Kindred Biosciences, Inc. (NASDAQ: KIN) (“KindredBio”) breached their fiduciary duties or violated the...
Jun 16, 2021 06:30 am ET
Elanco Announces Agreement to Acquire Kindred Biosciences
Elanco Animal Health Incorporated (NYSE: ELAN) and Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN) today announced the parties have entered into a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets. The acquisition further accelerates Elanco’s expansion in the attractive pet health market, particularly advancing Elanco’s presence in the fast-growing billion-dollar dermatology category.
Jun 16, 2021 06:30 am ET
Elanco Announces Agreement to Acquire Kindred Biosciences
GREENFIELD, Ind. and SAN FRANCISCO, June 16, 2021 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) and Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN) today announced the parties have entered into a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets. The acquisition further accelerates Elanco's expansion in the attractive pet health market, particularly advancing Elanco's presence in the fast-growing billion-dollar dermatology category.
Jun 15, 2021 02:00 am ET
TriRx Enters Agreement for the Acquisition of Elanco Animal Health Facilities in Shawnee, Kansas and Speke, United Kingdom
NORWALK, Conn., June 15, 2021 /PRNewswire/ -- TriRx Pharmaceutical Services Inc., a leading international CDMO, today announced an agreement to acquire two facilities from Elanco Animal Health Incorporated (NYSE: ELAN). Elanco is a global animal health leader dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The sites are located in Shawnee, Kansas and Speke, United Kingdom, and will expand the manufacturing footprint of TriRx, adding to its existing pharmaceutical facilities in Huntsville, Alabama, and Segré, France.
Jun 10, 2021 06:30 am ET
Elanco Releases Environmental, Social and Governance (ESG) Summary
Elanco Animal Health Incorporated (NYSE: ELAN) today released its 2020 Environmental, Social and Governance (ESG) Summary, including disclosure on climate-related and workforce m
Jun 09, 2021 09:15 am ET
Elanco Announces Exit of Three Manufacturing Sites, Streamlining Footprint
The sale of the sites includes the physical assets at both locations along with the transfer of approximately 600 employees, subject to necessary consultation based on local regulations. The companies have also entered into a long-term supply agreement for the facilities to continue to manufacture existing Elanco products.
Jun 04, 2021 08:00 am ET
Elanco Announces Addition of Marcela A. Kirberger as General Counsel and Corporate Secretary
Today, Elanco Animal Health Incorporated (NYSE: ELAN) named Marcela A. Kirberger as general counsel and corporate secretary. She joins the Elanco Executive Committee at the company’s Greenfield, Indiana-based headquarters on June 22.
May 25, 2021 07:00 am ET
EVAH Announces Acquisition and Development Agreements for Four Technologies from Elanco
This provides EVAH with a diversified portfolio of technologies targeting three species
May 20, 2021 05:00 pm ET
Elanco to Participate in Upcoming Investor Conferences
Elanco Animal Health Incorporated (NYSE: ELAN) today announced its participation in two investor conferences in June.
May 11, 2021 08:00 am ET
Elanco Launches Product for U.S. Poultry Producers, Providing a Flexible Option for Cocci Control
Elanco Animal Health Incorporated (NYSE: ELAN) launches ZoaShield™ in the United States, which offers poultry producers a proven and flexible zoalene solution that keeps coccidiosis under control in an easy, manageable way.
May 07, 2021 06:30 am ET
Elanco Animal Health Reports First Quarter 2021 Results
Elanco Animal Health Incorporated (NYSE: ELAN) today reported strong financial results for the first quarter of 2021, provided guidance for the second quarter of 2021, and updated guidance for the full year 2021. The results reflect the inclusion of the Bayer Animal Health business Elanco acquired on August 1, 2020.
May 04, 2021 08:00 am ET
Elanco Animal Health Introduces First Oral Flea and Tick Product for Cats, Credelio® CAT (lotilaner)
Veterinarians in the U.S. now have a new, innovative option for flea and tick control as Elanco Animal Health Incorporated (NYSE: ELAN) introduces Credelio Cat, the first oral flea and tick product for cats.
Apr 21, 2021 04:30 pm ET
Elanco Animal Health and Ducks Unlimited Announce Partnership to Advance Beef Industry Environmental Stewardship Efforts
Today, Elanco and Ducks Unlimited announced a partnership emphasizing the strong bond between environmental sustainability and agriculture – specifically beef cattle production – across North America. Beginning in 2021 and through 2023, Elanco will invest $50,000 annually with Ducks Unlimited to help purchase grass seed to support reseeding efforts on working lands in western Kansas.
Apr 07, 2021 08:30 am ET
Elanco Confirms Date and Conference Call for First Quarter 2021 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2021 financial results on Friday, May 7, 2021. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Mar 19, 2021 06:30 am ET
Elanco Stands Behind Seresto and its Safety Profile
Based on recent misleading media coverage, a U.S. House of Representatives subcommittee chair made a request to Elanco Animal Health, Incorporated (NYSE: ELAN) to temporarily remove Seresto collars from the market. Elanco reiterates that it stands behind the safety data of Seresto generated for its registration and monitored via post-marketing surveillance.
Feb 24, 2021 06:30 am ET
Elanco Animal Health Reports Fourth Quarter and Full Year 2020 Results
Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year of 2020, increased guidance for full year 2021, and provided initial guidance for the first quarter of 2021. The results reflect the inclusion of the Bayer Animal Health business that Elanco acquired on August 1, 2020.
Feb 22, 2021 08:00 am ET
Elanco General Counsel Michael-Bryant Hicks to Depart After Successful Company Stand-Up and Acquisition Completion
Elanco Animal Health Incorporated (NYSE: ELAN) today announced the departure of executive vice president Michael-Bryant Hicks (“Hicks”). He joined Elanco in 2018 as General Counsel and Corporate Secretary to prepare the company for IPO, build the Legal department structure for the stand-alone company, and complete the successful acquisition of Bayer Animal Health.
Feb 19, 2021 08:00 am ET
Elanco Achieves Important Innovation Milestones, Momentum to Start 2021
Elanco Animal Health Incorporated (NYSE: ELAN) today announces four important innovation milestones, including two product approvals, amid a string of recent progress on its innovation commitments.
Feb 18, 2021 08:30 am ET
Elanco to Participate in the Cowen 41st Annual Health Care Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Cowen 41st Annual Health Care Conference on Tuesday, March 2, 2021. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 2:50 p.m. ET.
Feb 12, 2021 08:30 am ET
Elanco to Participate in the BofA Securities Animal Health Virtual Summit
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the BofA Securities Animal Health Virtual Summit on Thursday, February 25, 2021. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 3:30 p.m. ET.
Jan 27, 2021 08:30 am ET
Elanco Confirms Date and Conference Call for Fourth Quarter 2020 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter 2020 financial results on Wednesday, February 24, 2021. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Jan 26, 2021 08:00 am ET
Elanco Announces Next Wave of Restructuring to Drive Operational Efficiencies Post Bayer Acquisition
Elanco Animal Health Incorporated (NYSE: ELAN) today announced the next step in its ongoing efforts to improve operational efficiency. The proposed actions are focused on streamlining processes and delivering increased efficiency in functional areas while, importantly, improving the productivity of Elanco’s investments in innovation. These actions build on the September 2020 restructuring that focused mainly on optimizing the combined Elanco and Bayer Animal Health commercial operations.
Jan 19, 2021 07:00 am ET
Dr. Marijn Dekkers Named Chairman of AgBiome Board of Directors
RESEARCH TRIANGLE PARK, N.C., Jan. 19, 2021 /PRNewswire/ -- AgBiome, a leader in developing innovative products from the Earth's microbial communities, announced Dr. Marijn Dekkers as the company's Chairman, effective January 1, 2021.
Jan 11, 2021 07:00 am ET
Elanco Begins Next Phase of Integration Post-Bayer Animal Health Acquisition; Executive Committee Member Sarena Lin to Depart
Today Elanco Animal Health Incorporated (NYSE: ELAN) announced that executive vice president of Transformation and Technology, Sarena Lin, will take a role outside of the company at the end of January. Lin has led the company’s stand up and integration efforts over the last year, helping position Elanco for its final phases of integration and value capture.
Dec 22, 2020 08:30 am ET
Elanco to Participate in the 39th Annual J.P. Morgan Healthcare Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts. He is scheduled to present at 7:30 a.m. ET.
Dec 15, 2020 08:00 am ET
Elanco Animal Health Hosts Investor Day, Demonstrating Inflection Point Toward Accelerated Value Creation
Elanco Animal Health Incorporated (NYSE: ELAN) today will host its Investor Day, where the executive leadership team will outline the company’s strengthened and expanded Innovation, Portfolio, Productivity (IPP) strategy, introduce a long-term growth algorithm for accelerated value creation, and discuss 2020 financial targets and 2021 guidance.
Dec 14, 2020 04:05 pm ET
Elanco Appoints New Independent Directors to the Board and Expands Innovation and Operational Oversight
Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed distinguished healthcare executive, animal health director and investor William F. Doyle to the Board of Directors, effective immediately. Elanco has also expanded the Board and appointed Scott Ferguson, managing partner of Sachem Head Capital Management (Sachem Head), and Paul Herendeen, chief financial officer of Bausch Health, to the Board, effective immediately, and the company has entered into a cooperation agreement with Sachem Head. Under the terms of the agreement, Sachem Head has agreed to certain vot
Dec 11, 2020 08:00 am ET
Elanco Announces Agreement with KindredBio to Bring First-of-its-Kind Canine Parvovirus Therapy to Market
Elanco Animal Health Incorporated (NYSE: ELAN) today announced an agreement with Kindred Biosciences (NASDAQ: KIN) to acquire exclusive global rights to KIND-030, a first-of-its-kind monoclonal antibody being developed for the treatment and prevention of canine parvovirus (CPV). This deadly disease impacts at least 250,000 puppies annually in the U.S., according to Banfield Pet Hospital1, with no approved treatment available.
Dec 11, 2020 07:00 am ET
Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal Antibody
SAN FRANCISCO, Dec. 11, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced an agreement granting Elanco Animal Health Incorporated exclusive global rights to KIND-030, a monoclonal antibody targeting canine parvovirus (CPV). As part of the agreement, KindredBio also has a right of last refusal to manufacture certain of Elanco's other monoclonal antibody products.  
Dec 04, 2020 07:30 am ET
Elanco Animal Health Selects Indiana as Home for Global HQ and Future Footprint Consolidation
After a rigorous multi-state search, Elanco Animal Health, Inc. (NYSE: ELAN) today announced Indiana as its base for future global consolidated operations, anchored by a new streamlined fit-for-purpose global headquarters in downtown Indianapolis. The move represents another step in Elanco’s plan to capture economic value through global footprint consolidation after its August acquisition of Bayer’s animal health business.
Dec 01, 2020 08:30 am ET
Elanco to Host Virtual Investor Day, Provide 2021 Guidance
Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it will host a virtual investor day on Tuesday, December 15, 2020. The event will feature presentations from Jeff Simmons, Elanco president and CEO, along with other members of Elanco’s executive leadership team. Management will outline its strategy to drive long-term shareholder value while also providing financial guidance for 2021. A live question and answer session will follow the presentations.
Nov 30, 2020 10:00 pm ET
Elanco Announces Pricing of Public Offering of Common Stock by Selling Shareholder
Elanco Animal Health Incorporated (NYSE: ELAN) today announced the pricing of the previously announced public offering of 54,500,000 shares of its common stock held by Bayer World Investments B.V, an affiliate of Bayer AG, at $30.25 per share. Bayer World Investments B.V. is the sole selling shareholder and has also granted to the underwriters an option to purchase up to an additional 8,175,000 shares of common stock. Elanco will not issue shares in the offering and will not receive any proceeds from the sale of the shares by the selling shareholder in the offering. The offering is expected to
Nov 30, 2020 07:00 am ET
Elanco Announces Public Offering of Common Stock by Selling Shareholder
Elanco Animal Health Incorporated (NYSE: ELAN) announced today the launch of a public offering of 54,500,000 shares of its common stock held by Bayer World Investments B.V, an affiliate of Bayer AG. Bayer World Investments B.V. will be the sole selling shareholder and will also grant to the underwriters an option to purchase up to an additional 8,175,000 shares of common stock. Elanco will not issue shares in the offering and will not receive any proceeds from the sale of the shares by the selling shareholder in this offering.
Nov 19, 2020 08:30 am ET
Elanco to Participate in the 3rd Annual Evercore ISI Virtual HealthCONx Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, December 1, 2020. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 1:00 p.m. ET.
Nov 06, 2020 06:30 am ET
Elanco Animal Health Reports Third Quarter 2020 Results
Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the third quarter of 2020 and provided guidance for the fourth quarter of 2020. The results reflect the inclusion of the Bayer Animal Health business that Elanco acquired on August 1, 2020.
Oct 29, 2020 08:00 am ET
Elanco to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on Monday, November 9, 2020. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 3:30 p.m. ET.
Oct 28, 2020 08:00 am ET
Elanco’s Elura™ (capromorelin oral solution) Gains U.S. Approval
With the U.S. Food and Drug Administration (FDA) approval of Elura™ (capromorelin oral solution), a new prescription medication to manage weight loss in cats with chronic kidney disease (CKD), Elanco Animal Health (NYSE: ELAN) expands its feline offerings while addressing an unmet need in an increasingly common condition as cats age.
Oct 27, 2020 08:00 am ET
Elanco Releases Healthy Purpose™ 2030 Sustainability Commitments to Improve Health of Animals, People and Planet
Elanco Animal Health Incorporated (NYSE: ELAN) today announced its first sustainability commitments, just two years after becoming an independent company. The decade-long commitments support the SDGs, address societal challenges and underscore Elanco’s role in improving the health of animals, which also improves the health of people and the planet.
Oct 13, 2020 03:00 pm ET
Elanco Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
Elanco Animal Health Incorporated (“Elanco”) (NYSE: ELAN) has received a notification of an unsolicited “mini-tender” offer by TRC Capital Investment Corporation (“TRC Capital”) to purchase up to 4,000,000 shares of Elanco common stock, representing approximately 1.00% of the outstanding shares of Elanco common stock.
Oct 09, 2020 08:30 am ET
Elanco Confirms Date and Conference Call for Third Quarter 2020 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2020 financial results on Friday, November 6, 2020. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Sep 30, 2020 07:30 am ET
Elanco Announces Restructuring to Drive Synergies From Bayer Animal Health Acquisition
Elanco Animal Health Incorporated (NYSE:ELAN) today announced its first business restructuring just two months following the closing of its acquisition of Bayer Animal Health. The company also noted it has started to de-lever by making a $100 million payment on its term loan.
Sep 08, 2020 05:00 pm ET
Elanco to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 2:00 p.m. EDT.
Aug 03, 2020 06:00 am ET
Elanco Closes Acquisition of Bayer Animal Health
Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Bayer Animal Health. The transaction, valued at $6.89 billion, expands Elanco’s scale and capabilities, positioning the company for the long term as a leader in the attractive, durable animal health industry.
Jul 30, 2020 06:30 am ET
Elanco Animal Health Reports 2020 Second Quarter Results
Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the second quarter of 2020. The performance reflects the reduction of channel inventory and lower levels of demand resulting from the COVID-19 pandemic. Elanco's innovation, portfolio, and productivity strategy continues to be the focus, and its long-term industry fundamentals and durability remain intact.
Jul 28, 2020 10:00 am ET
Jason Kuhlemeier Joins AgBiome as VP of Marketing
RESEARCH TRIANGLE PARK, N.C., July 28, 2020 /PRNewswire/ -- AgBiome, a leader in developing innovative products from the Earth's microbial communities, announced Jason Kuhlemeier has joined the company as Vice President of Marketing. Kuhlemeier has a long successful track record of working in the agriculture industry.
Jul 21, 2020 10:00 am ET
Gerald Coward Joins AgBiome as CFO
RESEARCH TRIANGLE PARK, N.C., July 21, 2020 /PRNewswire/ -- AgBiome®, a leader in developing innovative products from the Earth's microbial communities, announced Gerald Coward has joined the company as its Chief Financial Officer. Gerald will lead the finance team from the company's headquarters in Research Triangle Park, NC, effective immediately.
Jul 20, 2020 11:00 am ET
DEADLINE ALERT for ELAN, R, and HBB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 20, 2020 09:33 am ET
ELAN FINAL DEADLINE TODAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Reminds Elanco Animal Health Incorporated Investors of Important July 20 Deadline in Securities Class Action – ELAN
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Elanco Animal Health Incorporated (NYSE: ELAN) between January 10, 2020 and May 6, 2020, inclusive (the “Class Period”), of the important July 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Elanco investors under the federal securities laws.
Jul 20, 2020 08:04 am ET
Elanco Animal Health Investors With Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C. – Elanco Animal Health Investors Reminded of July 20, 2020 Lead Plaintiff Deadline
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) to determine whether Elanco may have violated federal securities laws. Investors...
Jul 19, 2020 10:50 pm ET
ELANCO 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Elanco Animal
NEW ORLEANS, July 19, 2020 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until July 20, 2020 to file lead plaintiff applications in a securities class action lawsuit against Elanco Animal Health Incorporated (NYSE: ELAN), if they purchased the Company's securities between January 10, 2020 and May 6, 2020, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of Indiana.
Jul 18, 2020 10:50 pm ET
ELANCO 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Elanco Animal Health Incorporated - ELAN
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until July 20, 2020 to file lead plaintiff applications in a securities class action lawsuit against Elanco Animal Health Incorporated (NYSE: ELAN), if they purchased the Company’s securities between January 10, 2020 and May 6, 2020, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of Indiana.
Jul 18, 2020 08:57 am ET
LEGAL DEADLINE ALERT—The Law Firm of Barbuto & Johansson, P.A. Reminds R, ELAN, FSCT and ENPH Shareholders of Important Class Action Deadlines
Barbuto & Johansson, P.A. (“BARJO” or the “Firm”) and Of Counsel, Neil Rothstein, Esq. (with over 30 years of Securities Class Action experience, including cases against ENRON and HALLIBURTON) remind investors of important deadlines approaching in...
Jul 17, 2020 10:50 pm ET
ELANCO 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Elanco Animal
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until July 20, 2020 to file lead plaintiff applications in a securities class action lawsuit against Elanco Animal Health Incorporated (NYSE: ELAN), if they purchased the Company’s securities between January 10, 2020 and May 6, 2020, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of Indiana.
Jul 17, 2020 01:40 pm ET
ELAN FINAL DEADLINE: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Reminds Elanco Animal Health Incorporated Investors of Important Monday Deadline in Securities Class Action – ELAN
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Elanco Animal Health Incorporated (NYSE: ELAN) between January 10, 2020 and May 6, 2020, inclusive (the “Class Period”), of the important July 20, 2020 lead...
Jul 17, 2020 12:00 pm ET
ELAN Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Elanco Animal Health Incorporated and Lead Plaintiff Deadline: July 20, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated  ("Elanco" or "the Company") (NYSE: ELAN) and certain of its officers, on behalf of...
Jul 17, 2020 12:00 pm ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Elanco Animal Health Incorporated (ELAN)
The Law Offices of Frank R. Cruz reminds investors of the upcoming July 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE:
Jul 16, 2020 05:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elanco Animal Health Incorporated - ELAN
Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Jul 16, 2020 04:05 pm ET
PetIQ, Inc. Receives FTC Approval to Close Acquisition of the Capstar® Portfolio of Products
PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced they have received  final approval from the U.S. Federal Trade Commission (“FTC”) and will close the $95 million cash acquisition...
Jul 16, 2020 08:30 am ET
First-of-its-Kind Study Shows 1 in 5 Dogs Visiting Dog Parks in Major U.S. Cities Tested Positive for Intestinal Parasites
A new survey of more than 1,000 US pet owners shows that recent COVID-19 restrictions have increased our reliance on our four-legged family members. Further, pet parents report plans to keep canine friends integrated into their daily lives after the pandemic is over, including working from home, errands and social time.2
Jul 15, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ELAN, R INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Elanco Animal Health Incorporated (ELAN)Class...
Jul 15, 2020 11:07 am ET
Elanco Receives U.S. Federal Trade Commission Approval for Acquisition of Bayer Animal Health
Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the company has received unanimous approval from the U.S. Federal Trade Commission (FTC) for its acquisition of Bayer Animal Health, a division of Bayer AG (ETR: BAYN). The FTC decision represents the final antitrust clearance needed to complete the transaction, which continues on track for closing at the beginning of August.
Jul 14, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ELAN, FSCT, R and WFC
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Elanco Animal Health Incorporated (ELAN)Investors Affected: January 10, 2020 - May 6, 2020Lead Plaintiff Motion...
Jul 14, 2020 12:00 pm ET
DEADLINE ALERT for ELAN, R, and HBB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 14, 2020 11:00 am ET
ELAN Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Elanco Animal Health Incorporated and Lead Plaintiff Deadline: July 20, 2020
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
Jul 13, 2020 11:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elanco Animal Health Incorporated - ELAN
NEW YORK, July 13, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 13, 2020 11:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elanco Animal Health Incorporated - ELAN
NEW YORK, July 13, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 13, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ELAN, FSCT, R, WFC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Elanco Animal Health Incorporated (ELAN) Class Period: 1/10/2020 - 5/6/2020Lead Plaintiff Motion...
Jul 11, 2020 11:48 am ET
LEGAL DEADLINE ALERT—The Law Firm of Barbuto & Johansson, P.A. Reminds LOPE, R, ELAN and WFC Shareholders of Important Class Action Deadlines
Barbuto & Johansson, P.A. (“BARJO” or the “Firm”) and Of Counsel, Neil Rothstein, Esq. (with over 30 years of Securities Class Action experience, including cases against ENRON and HALLIBURTON) remind investors of important deadlines approaching in...
Jul 10, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ELAN, R INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Elanco Animal Health Incorporated (ELAN) Class...
Jul 10, 2020 05:00 pm ET
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Reminds Elanco Animal Health Incorporated Investors of Important July 20 Deadline in Securities Class Action - ELAN
NEW YORK, July 10, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Elanco Animal Health Incorporated (NYSE: ELAN) between January 10, 2020 and May 6, 2020, inclusive (the "Class Period") of the important July 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Elanco investors under the federal securities laws.
Jul 10, 2020 12:00 pm ET
ELAN Shareholder Update: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Elanco Animal Health Incorporated and Lead Plaintiff Deadline: July 20, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated  ("Elanco" or "the Company") (NYSE: ELAN) and certain of its officers, on behalf of...
Jul 09, 2020 12:46 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of  Elanco Animal Health Incorporated - ELAN
Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,...
Jul 08, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ELAN, FSCT, R, WFC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Elanco Animal Health Incorporated (ELAN) Class Period: 1/10/2020 - 5/6/2020Lead Plaintiff Motion...
Jul 08, 2020 01:50 pm ET
DEADLINE ALERT for ELAN, R, and HBB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 08, 2020 08:30 am ET
Elanco Confirms Date and Conference Call for Second Quarter 2020 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2020 financial results on Thursday, July 30, 2020. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
Jul 07, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ELAN, FSCT, R and WFC
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Elanco Animal Health Incorporated (ELAN) Investors Affected: January 10, 2020 - May 6, 2020Lead Plaintiff Motion...
Jul 07, 2020 04:37 pm ET
ROSEN, A TRUSTED AND TOP RANKED FIRM, Reminds Elanco Animal Health Incorporated Investors of Important July 20 Deadline in Securities Class Action - ELAN
NEW YORK, July 7, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Elanco Animal Health Incorporated (NYSE: ELAN) between January 10, 2020 and May 6, 2020, inclusive (the "Class Period") of the important July 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Elanco investors under the federal securities laws.
Jul 07, 2020 01:34 pm ET
Elanco Animal Health Investors With Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) to determine whether Elanco may have violated federal securities laws. Investors...
Jul 07, 2020 11:30 am ET
DEADLINE ALERT for LOPE, CONN, ELAN, R: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jul 06, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ELAN, FSCT, R, WFC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Elanco Animal Health Incorporated (ELAN)Class...
Jul 06, 2020 02:40 am ET
LEGAL DEADLINE ALERT—The Law Firm of Barbuto & Johansson, P.A. Reminds LOPE, R, ELAN and WFC Shareholders of Important Class Action Deadlines
Barbuto & Johansson, P.A. (“BARJO” or the “Firm”) and Of Counsel, Neil Rothstein, Esq. (with over 30 years of Securities Class Action experience, including cases against ENRON and HALLIBURTON) remind investors of important deadlines approaching in...
Jul 03, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ELAN, FSCT, R, WFC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Elanco Animal Health Incorporated (ELAN)Class Period: 1/10/2020 - 5/6/2020Lead Plaintiff Motion...
Jul 03, 2020 03:38 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elanco Animal Health Incorporated - ELAN
Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,...
Jul 02, 2020 03:30 pm ET
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Reminds Elanco Animal Health Incorporated Investors of Important July 20 Deadline in Securities Class Action – ELAN
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Elanco Animal Health Incorporated (NYSE: ELAN) between January 10, 2020 and May 6, 2020, inclusive (the “Class Period”) of the important July 20, 2020 lead...
Jul 02, 2020 12:30 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Elanco Animal Health Incorporated (ELAN)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 20, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN)...
Jul 01, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ELAN, FSCT, R, WFC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Elanco Animal Health Incorporated (ELAN)Class...
Jun 30, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ELAN, FSCT, R and WFC
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Elanco Animal Health Incorporated (ELAN)Investors Affected: January 10, 2020 - May 6, 2020Lead Plaintiff Motion...
Jun 30, 2020 06:14 pm ET
Shareholder Alert: Robbins LLP Announces Elanco Animal Health Incorporated (ELAN) Accused of Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of Elanco Animal Health Incorporated (NYSE: ELAN) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between January 10, 2020 and May 6, 2020. Elanco is an animal health company that develo
Jun 30, 2020 10:00 am ET
DEADLINE ALERT for ELAN, R, and HBB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 30, 2020 10:00 am ET
AgBiome Secures Patent Protection for New Connate Product Line
RESEARCH TRIANGLE PARK, N.C., June 30, 2020 /PRNewswire/ -- AgBiome®, a leader in developing innovative products from the Earth's microbial communities, announced a recent patent directed toward the Connate™ product line granted in the United States, further strengthening AgBiome's IP Protection around novel product offerings. Connate products, currently in development,  have the same biological component such as Howler® fungicide with the addition of a synthetic chemistry. Connate products aim to meet the grower demands for effective products while reducing the amount of chemical residues o
Jun 29, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ELAN, FSCT, R, WFC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Elanco Animal Health Incorporated (ELAN) Class Period: 1/10/2020 - 5/6/2020Lead Plaintiff Motion...
Jun 29, 2020 09:13 pm ET
LEGAL DEADLINE ALERT—The Law Firm of Barbuto & Johansson, P.A. Reminds ELAN, FSCT, PRA and USO Shareholders of Important Class Action Deadlines
Barbuto & Johansson, P.A. (“BARJO” or the “Firm”) and Of Counsel, Neil Rothstein, Esq. (with over 30 years of Securities Class Action experience, including cases against ENRON and HALLIBURTON) remind investors of important deadlines approaching in...
Jun 29, 2020 11:00 am ET
DEADLINE ALERT for CONN, ELAN, R, HBB: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 29, 2020 09:15 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of  Elanco Animal Health Incorporated - ELAN
Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,...
Jun 27, 2020 09:24 am ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm
SAN DIEGO, June 27, 2020 /PRNewswire/ -- Johnson Fistel, LLP, announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation.  The lead plaintiff can select a law firm of its choice.  An investor's ability to share in any potential future recovery is not dependent upon serving as
Jun 26, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ELAN, FSCT, R, WFC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Elanco Animal Health Incorporated (ELAN) Class...
Jun 24, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ELAN, FSCT, R, WFC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Elanco Animal Health Incorporated (ELAN) Class Period: 1/10/2020 - 5/6/2020Lead Plaintiff Motion...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.